<DOC>
	<DOCNO>NCT00886496</DOCNO>
	<brief_summary>RATIONALE : Recombinant human mannose-binding lectin ( MBL ) may effective prevent infection young patient fever neutropenia receive chemotherapy blood disease cancer . PURPOSE : This phase I trial study side effect best dose recombinant human mannose-binding lectin treat young patient MBL deficiency fever neutropenia .</brief_summary>
	<brief_title>Recombinant Human Mannose-Binding Lectin ( MBL ) Treating Young Patients With MBL Deficiency Fever Neutropenia</brief_title>
	<detailed_description>OBJECTIVES : Primary - Determine safety tolerability recombinant human mannose-binding lectin ( MBL ) pediatric patient MBL deficiency fever neutropenia undergo cytotoxic chemotherapy hematological/oncological disease . - Determine pharmacokinetics drug patient . Secondary - Determine pharmacodynamic effect drug patient . - Determine nonspecific activation complement vivo determination C3d complement activation patient treat drug . - Determine ex-vivo activity recombinant MBL opsonization capacity patient ' serum yeast bacteria . - Determine immunogenicity drug patient . - Determine incidence duration fever breakthrough infection patient treated drug . OUTLINE : This non-randomized , multicenter , open-label , prospective , cohort study . Patients assign 1 2 treatment group . - Group I : Patients receive low-dose recombinant human mannose-binding lectin ( MBL ) IV 1 hour within 72 hour onset fever neutropenia . - Group II : Patients receive high-dose recombinant human MBL IV 1 hour within 72 hour onset fever neutropenia . Patients undergo blood collection periodically study pharmacokinetic , pharmacodynamic , MBL immunogenicity , opsonization/phagocytosis study . After completion study treatment , patient follow 30 day . PROJECTED ACCRUAL : A total 48 patient accrue study .</detailed_description>
	<mesh_term>Lymphoma</mesh_term>
	<mesh_term>Syndrome</mesh_term>
	<mesh_term>Leukemia</mesh_term>
	<mesh_term>Myelodysplastic Syndromes</mesh_term>
	<mesh_term>Preleukemia</mesh_term>
	<mesh_term>Fever</mesh_term>
	<mesh_term>Neutropenia</mesh_term>
	<mesh_term>Hot Flashes</mesh_term>
	<criteria>DISEASE CHARACTERISTICS : Undergoing cytologic chemotherapy hematological/oncological disease Must meet follow criterion : Documented mannosebinding lectin ( MBL ) level &lt; 300 ng/mm³ within past week Fever ( oral temperature &gt; 100.4° F ) Neutropenia , define absolute neutrophil count ≤ 1,000/mm³ anticipation count fall 500/mm^3 Receiving broad spectrum antibiotic therapy fever neutropenia PATIENT CHARACTERISTICS : No serious illness , opinion principal investigator , would preclude study compliance No known allergic reaction mannosebinding lectin human plasma product Not pregnant nursing Negative pregnancy test Fertile patient must use effective barrier method contraception ≥ 30 day completion study treatment AST ALT ≤ 5 time upper limit normal ( ULN ) Bilirubin ≤ 2.5 time ULN Creatinine clearance &gt; 60 mL/min OR creatinine base age follow : No 0.8 mg/dL ( patient 5 year age ) No 1.0 mg/dL ( patient 69 year age ) No 1.2 mg/dL ( patient 1012 year age ) No 1.4 mg/dL ( patient 13 year age [ female ] ) No 1.5 mg/dL ( patient 1315 year age [ male ] ) No 1.7 mg/dL ( patient 16 year age [ male ] ) No poor venous access would preclude IV drug delivery multiple blood draw Patients hemodialysis must able tolerate IV fluid nondialysis day PRIOR CONCURRENT THERAPY : See Disease Characteristics More 30 day since prior investigational agent Investigational use FDAapproved drug allow No concurrent preparative regimen bone marrow hematopoietic stem cell transplantation No concurrent participation another clinical trial investigational agent</criteria>
	<gender>All</gender>
	<minimum_age>2 Years</minimum_age>
	<maximum_age>17 Years</maximum_age>
	<verification_date>August 2007</verification_date>
	<keyword>unspecified childhood solid tumor , protocol specific</keyword>
	<keyword>fever , sweat , hot flash</keyword>
	<keyword>neutropenia</keyword>
	<keyword>infection</keyword>
	<keyword>recurrent childhood small noncleaved cell lymphoma</keyword>
	<keyword>stage I II childhood small noncleaved cell lymphoma</keyword>
	<keyword>stage I childhood small noncleaved cell lymphoma</keyword>
	<keyword>stage II childhood small noncleaved cell lymphoma</keyword>
	<keyword>stage III IV childhood small noncleaved cell lymphoma</keyword>
	<keyword>stage III childhood small noncleaved cell lymphoma</keyword>
	<keyword>stage IV childhood small noncleaved cell lymphoma</keyword>
	<keyword>recurrent childhood lymphoblastic lymphoma</keyword>
	<keyword>stage I II childhood lymphoblastic lymphoma</keyword>
	<keyword>stage I childhood lymphoblastic lymphoma</keyword>
	<keyword>stage II childhood lymphoblastic lymphoma</keyword>
	<keyword>stage III IV childhood lymphoblastic lymphoma</keyword>
	<keyword>stage III childhood lymphoblastic lymphoma</keyword>
	<keyword>stage IV childhood lymphoblastic lymphoma</keyword>
	<keyword>childhood Burkitt lymphoma</keyword>
	<keyword>recurrent/refractory childhood Hodgkin lymphoma</keyword>
	<keyword>stage I childhood Hodgkin lymphoma</keyword>
	<keyword>stage II childhood Hodgkin lymphoma</keyword>
	<keyword>stage III childhood Hodgkin lymphoma</keyword>
	<keyword>stage IV childhood Hodgkin lymphoma</keyword>
	<keyword>childhood acute lymphoblastic leukemia remission</keyword>
	<keyword>recurrent childhood acute lymphoblastic leukemia</keyword>
	<keyword>untreated childhood acute lymphoblastic leukemia</keyword>
	<keyword>de novo myelodysplastic syndrome</keyword>
	<keyword>previously treat myelodysplastic syndrome</keyword>
	<keyword>secondary myelodysplastic syndrome</keyword>
	<keyword>childhood acute myeloid leukemia remission</keyword>
	<keyword>recurrent childhood acute myeloid leukemia</keyword>
	<keyword>untreated childhood acute myeloid leukemia myeloid malignancy</keyword>
	<keyword>childhood grade III lymphomatoid granulomatosis</keyword>
	<keyword>childhood nasal type extranodal NK/T-cell lymphoma</keyword>
	<keyword>recurrent childhood grade III lymphomatoid granulomatosis</keyword>
	<keyword>childhood diffuse large cell lymphoma</keyword>
	<keyword>childhood immunoblastic large cell lymphoma</keyword>
	<keyword>recurrent childhood large cell lymphoma</keyword>
	<keyword>stage I childhood large cell lymphoma</keyword>
	<keyword>stage II childhood large cell lymphoma</keyword>
	<keyword>stage III IV childhood large cell lymphoma</keyword>
	<keyword>stage III childhood large cell lymphoma</keyword>
	<keyword>stage IV childhood large cell lymphoma</keyword>
</DOC>